LENZ Therapeutics, Inc. (NASDAQ: LENZ) reported Q2 EPS of ($1.02), $0.05 better than the analyst estimate of ($1.07). Revenue for the quarter came in at $5.5 million versus the consensus estimate of $2.49 million.

For earnings history and earnings-related data on LENZ Therapeutics, Inc. (LENZ) click here.